AR077040A1 - Acidos carboxilicos alifaticos halogenados, oligomeros y/o polimeros de los mismos y su utilizacion para desvitalizar neoplasmas externos e internos - Google Patents
Acidos carboxilicos alifaticos halogenados, oligomeros y/o polimeros de los mismos y su utilizacion para desvitalizar neoplasmas externos e internosInfo
- Publication number
- AR077040A1 AR077040A1 ARP100102034A ARP100102034A AR077040A1 AR 077040 A1 AR077040 A1 AR 077040A1 AR P100102034 A ARP100102034 A AR P100102034A AR P100102034 A ARP100102034 A AR P100102034A AR 077040 A1 AR077040 A1 AR 077040A1
- Authority
- AR
- Argentina
- Prior art keywords
- aliphatic hydrocarbon
- compound
- hydrocarbon chain
- oligomer
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
- C07C59/315—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicacion 1: Un método para tratar una condicion médica asociada con tejido neoplásico en un sujeto que necesita dicho tratamiento, dicho método está caracterizado porque comprende la administracion al sujeto de una cantidad desvitalizante eficaz de un compuesto que tiene la formula general (1): una sal farmacéuticamente aceptable o un complejo del mismo, o un oligomero del mismo; donde: Y es O o S; Z es hidroxilo o tiol; A es una cadena de hidrocarburo alifático ramificada o no ramificada, sustituida o no sustituida, saturada o no saturada que tiene 1-20 átomos de carbono en su cadena principal; X es un sustituyente de halogeno de dicha cadena de hidrocarburo alifático; y n es un entero entre 1 y 10, representando la cantidad de sustituyentes de halogeno. Reivindicacion 2: El uso de un compuesto caracterizado porque tiene la formula general (1): una sal farmacéuticamente aceptable o un complejo del mismo, o un oligomero del mismo; donde: Y es O o S; Z es hidroxilo o tiol; A es una cadena de hidrocarburo alifático ramificada o no ramificada, sustituida o no sustituida, saturada o no saturada que tiene 1-20 átomos de carbono en su cadena principal; X es un sustituyente de halogeno de dicha cadena de hidrocarburo alifático; y n es un entero entre 1 y 10, representando la cantidad de sustituyentes de halogeno, para la fabricacion de un medicamento para tratar una condicion médica asociada con tejido neoplásico. Reivindicacion 3: Un compuesto caracterizado porque tiene la formula general (1): una sal farmacéuticamente aceptable o un complejo del mismo, o un oligomero del mismo; donde: Y es O o S; Z es hidroxilo o tiol; A es una cadena de hidrocarburo alifático ramificada o no ramificada, sustituida o no sustituida, saturada o no saturada que tiene 1-20 átomos de carbono en su cadena principal; X es un sustituyente de halogeno de dicha cadena de hidrocarburo alifático; y n es un entero entre 1 y 10, representando la cantidad de sustituyentes de halogeno, para utilizar en el tratamiento de una condicion médica asociada con tejido neoplásico. Reivindicacion 11: El método, compuesto o el uso de la reivindicacion 10, caracterizado porque dicho compuesto es ácido 2,2-dicloropropanoico. Reivindicacion 48: Una composicion farmacéutica caracterizada porque comprende, como ingrediente activo, el compuesto como se describio en cualquiera de las reivindicaciones 1 a 15, y un vehículo farmacéuticamente aceptable. Reivindicacion 51: La forma oligomérica de un compuesto caracterizado porque tiene la Formula general (1): una sal farmacéuticamente aceptable o un complejo del mismo, o un oligomero del mismo; donde: Y es O o S; Z es hidroxilo o tiol; A es una cadena de hidrocarburo alifático ramificada o no ramificada, sustituida o no sustituida, saturada o no saturada que tiene 1-20 átomos de carbono en su cadena principal; X es un sustituyente de halogeno de dicha cadena de hidrocarburo alifático; y n es un entero entre 1 y 10, representando la cantidad de sustituyentes de halogeno. Reivindicacion 56: Un proceso para preparar el oligomero de cualquiera de las reivindicaciones 51 a 53, dicho proceso está caracterizado porque comprende calentar una forma monomérica de un compuesto que tiene dicha formula general 1, en presencia de una solucion acuosa, a una temperatura comprendida entre 150°C y 250°C, obteniendo así, dicho oligomero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18522609P | 2009-06-09 | 2009-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077040A1 true AR077040A1 (es) | 2011-07-27 |
Family
ID=42578223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102034A AR077040A1 (es) | 2009-06-09 | 2010-06-09 | Acidos carboxilicos alifaticos halogenados, oligomeros y/o polimeros de los mismos y su utilizacion para desvitalizar neoplasmas externos e internos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9283199B2 (es) |
| EP (1) | EP2440198B1 (es) |
| JP (1) | JP2012529497A (es) |
| KR (1) | KR20120099360A (es) |
| CN (1) | CN102695503A (es) |
| AR (1) | AR077040A1 (es) |
| AU (1) | AU2010258231A1 (es) |
| BR (1) | BRPI1009037A2 (es) |
| CA (1) | CA2763862C (es) |
| EA (1) | EA201270016A1 (es) |
| HK (1) | HK1169594A1 (es) |
| MX (1) | MX2011013223A (es) |
| SG (3) | SG190612A1 (es) |
| WO (1) | WO2010143188A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120099360A (ko) | 2009-06-09 | 2012-09-10 | 마르디 메디신즈 리미티드 | 할로겐화 지방족 카르복실산류, 이의 올리고머 및/또는 폴리머, 및 외부 및 내부 신생물을 무력화시키는 용도 |
| RU2482856C2 (ru) | 2011-08-05 | 2013-05-27 | Общество С Ограниченной Ответственностью "Оксигон" | Комплексное соединение 2-хлорпропионата цинка и 2-хлорпропионовой кислоты, фармацевтическая композиция для лечения заболеваний кожи, способ ее получения и способ лечения поражений кожи, ногтей и видимых слизистых |
| US9963481B2 (en) | 2011-09-07 | 2018-05-08 | The Scripps Research Institute | Chiral oligomeric pentenoate amides as bio-oligomer mimetics |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US275258A (en) | 1883-04-03 | Edward palliser | ||
| US2734075A (en) * | 1953-04-06 | 1956-02-07 | a-dichloropropionic acid esters of the | |
| LU68060A1 (es) * | 1973-07-20 | 1975-04-11 | ||
| US4624851A (en) * | 1983-04-22 | 1986-11-25 | Elena Avram | Treatment of symptoms of neoplastic diseases |
| US4824955A (en) * | 1985-11-15 | 1989-04-25 | Nippon Kayaku Kabushiki Kaisha | Selenium oxy chloride-pyridine or bipyridine complexes |
| WO1995011699A1 (en) | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| DE4407484A1 (de) * | 1993-12-03 | 1995-06-08 | Werner Prof Dr Kreutz | Medikament zur Krebs-Therapie |
| US5716959A (en) * | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
| JPH09227388A (ja) * | 1996-02-15 | 1997-09-02 | Naganushi Tetsuaki | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤 |
| JPH10130153A (ja) * | 1996-10-28 | 1998-05-19 | Shiyumeidou:Kk | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる 抗悪性腫瘍剤 |
| US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| JP2000298346A (ja) * | 1999-04-14 | 2000-10-24 | Toray Ind Inc | ポジ型感放射線性組成物およびこれを用いたレジストパターンの製造法 |
| EP1293498A1 (en) | 2001-08-30 | 2003-03-19 | Mardi, Shalva | Selenium complex with haloethanoic acid or its anhydride, and use thereof in the topical treatment of neoplasms |
| US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
| JPWO2003105869A1 (ja) * | 2002-06-12 | 2005-10-13 | 天藤製薬株式会社 | 抗癌剤副作用抑制剤 |
| GB0220045D0 (en) * | 2002-08-29 | 2002-10-09 | Cxr Biosciences Ltd Sc 211745 | Methods |
| FR2845599B1 (fr) * | 2002-10-11 | 2005-01-07 | Lmd | Medicament comprenant une thiouree pour son utilisation en tant que depigmentant |
| EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| RU2261243C1 (ru) | 2004-01-19 | 2005-09-27 | Шалва Марди | Соли цинка и галоидкарбоновых кислот алифатического ряда для лечения новообразований кожи и видимых слизистых покровов |
| US20070149618A1 (en) * | 2004-02-17 | 2007-06-28 | Action Medicines, S.L. | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis |
| EP1789030A2 (en) * | 2004-08-30 | 2007-05-30 | Interstitial Therapeutics | Medical implant provided with inhibitors of atp synthesis |
| WO2006042062A2 (en) * | 2004-10-08 | 2006-04-20 | The Johns Hopkins University | Pyruvate dehydrogenase kinases as therapeutic targets for cancer and ischemic diseases |
| WO2006108276A1 (en) * | 2005-04-11 | 2006-10-19 | The Governors Of The University Of Alberta | A method of treating cancer using dichloroacetate |
| EP1746082A1 (en) | 2005-07-19 | 2007-01-24 | Anatoly Fyodorovich Tsyb | Salts of zinc and aliphatic haloid carboxylic acids for therapy of skin neoplasms and visible mucous coats |
| EP2633834A1 (en) * | 2005-12-06 | 2013-09-04 | Covidien LP | Bioabsorbable Surgical Composition |
| US20080187511A1 (en) * | 2006-10-25 | 2008-08-07 | University Of Pittsburgh-Of The Commonwealth | Ointment for cancer treatment |
| RU2366648C2 (ru) | 2007-08-28 | 2009-09-10 | Медилик Пте.Лтд. | Продукт взаимодействия двуокиси селена с алифатическими галоидкарбоновыми кислотами, способ получения продукта, раствор продукта и способ лечения доброкачественных, вирусных, предзлокачественных и злокачественных неметастазирующих поражений кожи, диспластических поражений видимых слизистых оболочек и иных поражений кожи |
| RU2375054C2 (ru) | 2007-10-18 | 2009-12-10 | Медилик Пте.Лтд. | Препарат для лечения поражений кожи, способ получения препарата (варианты) и способ лечения поражений кожи |
| KR20120099360A (ko) | 2009-06-09 | 2012-09-10 | 마르디 메디신즈 리미티드 | 할로겐화 지방족 카르복실산류, 이의 올리고머 및/또는 폴리머, 및 외부 및 내부 신생물을 무력화시키는 용도 |
| US10310824B2 (en) | 2011-09-07 | 2019-06-04 | Imagine Communications Corp. | Distributed ledger platform for computing applications |
| GB201216800D0 (en) | 2012-09-20 | 2012-11-07 | Immodulon Therapeutics Ltd | Novel use |
| JP6638087B2 (ja) | 2015-12-21 | 2020-01-29 | グーグル エルエルシー | メッセージ交換スレッド用の自動提案 |
| TWI745100B (zh) | 2020-09-25 | 2021-11-01 | 壟銓科技股份有限公司 | 背包式防彈衣 |
| US11924354B2 (en) | 2021-03-19 | 2024-03-05 | Jpmorgan Chase Bank, N.A. | Data center recovery pod systems and methods |
-
2010
- 2010-06-09 KR KR1020127000494A patent/KR20120099360A/ko not_active Application Discontinuation
- 2010-06-09 US US12/796,804 patent/US9283199B2/en not_active Expired - Fee Related
- 2010-06-09 SG SG2013033113A patent/SG190612A1/en unknown
- 2010-06-09 EP EP10731814.9A patent/EP2440198B1/en not_active Not-in-force
- 2010-06-09 CN CN2010800343389A patent/CN102695503A/zh active Pending
- 2010-06-09 WO PCT/IL2010/000455 patent/WO2010143188A2/en active Application Filing
- 2010-06-09 BR BRPI1009037A patent/BRPI1009037A2/pt not_active IP Right Cessation
- 2010-06-09 AU AU2010258231A patent/AU2010258231A1/en not_active Abandoned
- 2010-06-09 EA EA201270016A patent/EA201270016A1/ru unknown
- 2010-06-09 JP JP2012514593A patent/JP2012529497A/ja active Pending
- 2010-06-09 SG SG2011089281A patent/SG176636A1/en unknown
- 2010-06-09 AR ARP100102034A patent/AR077040A1/es unknown
- 2010-06-09 MX MX2011013223A patent/MX2011013223A/es not_active Application Discontinuation
- 2010-06-09 CA CA2763862A patent/CA2763862C/en not_active Expired - Fee Related
- 2010-06-09 SG SG2013033097A patent/SG190611A1/en unknown
-
2012
- 2012-10-17 HK HK12110254.6A patent/HK1169594A1/zh not_active IP Right Cessation
-
2015
- 2015-11-19 US US14/945,616 patent/US20160067198A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2440198A2 (en) | 2012-04-18 |
| US20160067198A1 (en) | 2016-03-10 |
| SG190612A1 (en) | 2013-06-28 |
| SG176636A1 (en) | 2012-01-30 |
| CA2763862C (en) | 2017-04-25 |
| AU2010258231A1 (en) | 2011-12-22 |
| WO2010143188A2 (en) | 2010-12-16 |
| HK1169594A1 (zh) | 2013-02-01 |
| EA201270016A1 (ru) | 2012-06-29 |
| WO2010143188A3 (en) | 2011-05-26 |
| EP2440198B1 (en) | 2016-01-06 |
| MX2011013223A (es) | 2012-06-19 |
| SG190611A1 (en) | 2013-06-28 |
| JP2012529497A (ja) | 2012-11-22 |
| CA2763862A1 (en) | 2010-12-16 |
| KR20120099360A (ko) | 2012-09-10 |
| BRPI1009037A2 (pt) | 2017-06-06 |
| US9283199B2 (en) | 2016-03-15 |
| CN102695503A (zh) | 2012-09-26 |
| US20110052641A1 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| ECSP14006132A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
| CL2017000830A1 (es) | Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino. | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| AR099134A1 (es) | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| AR084174A1 (es) | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica | |
| AR080072A1 (es) | Composicion farmaceutica solida con mejoradores y metodos para prepararla | |
| EA201490396A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| AR087863A1 (es) | Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| EA201390626A1 (ru) | Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| EA201792597A2 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| DK2895187T1 (da) | Daptomycinformuleringer og anvendelser deraf | |
| EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| AR077040A1 (es) | Acidos carboxilicos alifaticos halogenados, oligomeros y/o polimeros de los mismos y su utilizacion para desvitalizar neoplasmas externos e internos | |
| RU2009122281A (ru) | Средство для лечения заболеваний в ветеринарии на основе соли фосфония | |
| EA201650048A1 (ru) | Способ получения конъюгата гиалуронидазы с производными полиэтиленпиперазина и применение полученного конъюгата | |
| AR086876A1 (es) | Derivados heterociclicos de sulfonamida | |
| RU2017124364A (ru) | Проводимый в воде способ получения сложных эфиров масляной кислоты и натриевой соли гиалуроновой кислоты | |
| AR085655A1 (es) | Extracto de cinnamomum burmanii, proceso de extraccion y su uso como regulador por disminucion de la bomba de protones, inhibidor enzimatico, y mucoprotector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |